ZUMA-2 cohorts drive brexu-cel’s journey in relapsed/refractory mantle cell lymphoma, from high response rates to dose ...

The data showed notable responses, even among patients living with chronic lymphocytic leukemia (CLL) who had previous exposure to B-cell receptor–associated kinase inhibitors, the authors said.

Revuforj is approved for relapsed or refractory acute leukemia with KMT2A translocation in patients aged 1 year and older. The AUGMENT-101 trial showed a 21.2% complete remission rate with a median ...

Explore how BTK resistance drives poor outcomes in relapsed mantle cell lymphoma and why ZUMA-2 CAR T therapy emerges as a ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...

Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce that Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, has been registered by the ...

Carvykti is a B-cell maturation antigen-directed genetically modified autologous chimeric antigen receptor T-cell therapy. The Food and Drug Administration (FDA) has approved Carvykti ® ...

The ORR was 69% (95% CI, 61-76) in the zanubrutinib arm and 46% (95% CI, 34-58) in the obinutuzumab monotherapy arm. The Food and Drug Administration (FDA) has granted accelerated approval to Brukinsa ...

Novel targeted therapies for R/R CLL, including venetoclax plus rituximab, acalabrutinib, and zanubrutinib, have favorable safety profiles. Bendamustine plus rituximab showed a lower risk of severe ...

A single-center real-world study compares the effectiveness and toxicity of chimeric antigen receptor T-cell therapy vs ...

A childhood cancer diagnosis can be unpredictable. What will the treatment be? Will it work? Will my child relapse? Ailani Myers, 9, has relapsed seven times, but her motto remains the same. "We've ...